Status:
RECRUITING
Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Lead Sponsor:
University of California, Irvine
Conditions:
Pregnancy, High Risk
Anticoagulants
Eligibility:
FEMALE
18+ years
Phase:
PHASE4
Brief Summary
Pregnancy is associated with a increased risk of developing blood clots. There is nearly a 5 times greater risk of developing a blood clot in pregnancy. Lovenox is a medication that helps to prevent t...
Eligibility Criteria
Inclusion
- Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy.
- Participants must be age 18 or older.
Exclusion
- Women with multiples.
- Women less than age 18
- History of Heparin Induced Thrombocytopenia (HIT)
- Allergy to enoxaparin
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT04861103
Start Date
October 1 2020
End Date
July 31 2027
Last Update
October 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California Irvine
Orange, California, United States, 92868